267 related articles for article (PubMed ID: 37453330)
1. Quinazoline-based VEGFR-2 inhibitors as potential anti-angiogenic agents: A contemporary perspective of SAR and molecular docking studies.
Moradi M; Mousavi A; Emamgholipour Z; Giovannini J; Moghimi S; Peytam F; Honarmand A; Bach S; Foroumadi A
Eur J Med Chem; 2023 Nov; 259():115626. PubMed ID: 37453330
[TBL] [Abstract][Full Text] [Related]
2. Novel 2-chloro-4-anilino-quinazoline derivatives as EGFR and VEGFR-2 dual inhibitors.
Barbosa ML; Lima LM; Tesch R; Sant'Anna CM; Totzke F; Kubbutat MH; Schächtele C; Laufer SA; Barreiro EJ
Eur J Med Chem; 2014 Jan; 71():1-14. PubMed ID: 24269511
[TBL] [Abstract][Full Text] [Related]
3. Design and synthesis of novel pyridazinoquinazoline derivatives as potent VEGFR-2 inhibitors: In vitro and in vivo study.
El-Gazzar MG; El-Hazek RM; Zaher NH; El-Ghazaly MA
Bioorg Chem; 2019 Nov; 92():103251. PubMed ID: 31525526
[TBL] [Abstract][Full Text] [Related]
4. Quinazoline-based multi-tyrosine kinase inhibitors: synthesis, modeling, antitumor and antiangiogenic properties.
Conconi MT; Marzaro G; Urbani L; Zanusso I; Di Liddo R; Castagliuolo I; Brun P; Tonus F; Ferrarese A; Guiotto A; Chilin A
Eur J Med Chem; 2013 Sep; 67():373-83. PubMed ID: 23900004
[TBL] [Abstract][Full Text] [Related]
5. Discovery of Dioxino[2,3-f]quinazoline derivative VEGFR-2 inhibitors exerting significant antipro-liferative activity in HUVECs and mice.
Fan H; Wei D; Zheng K; Qin X; Yang L; Yang Y; Duan Y; Xu Y; Hu L
Eur J Med Chem; 2019 Aug; 175():349-356. PubMed ID: 31096155
[TBL] [Abstract][Full Text] [Related]
6. Novel VEGFR-2 Kinase Inhibitors as Anticancer Agents: A Review Focusing on SAR and Molecular Docking Studies (2016-2021).
S V; Kajal K; Mondal S; Wahan SK; Das Kurmi B; Das Gupta G; Patel P
Chem Biodivers; 2023 Feb; 20(2):e202200847. PubMed ID: 36721068
[TBL] [Abstract][Full Text] [Related]
7. Discovery of Potent VEGFR-2 Inhibitors based on Furopyrimidine and Thienopyrimidne Scaffolds as Cancer Targeting Agents.
Aziz MA; Serya RA; Lasheen DS; Abdel-Aziz AK; Esmat A; Mansour AM; Singab AN; Abouzid KA
Sci Rep; 2016 Apr; 6():24460. PubMed ID: 27080011
[TBL] [Abstract][Full Text] [Related]
8. Identification of new pyrrolo[2,3-d]pyrimidines as potent VEGFR-2 tyrosine kinase inhibitors: Design, synthesis, biological evaluation and molecular modeling.
Adel M; Serya RAT; Lasheen DS; Abouzid KAM
Bioorg Chem; 2018 Dec; 81():612-629. PubMed ID: 30248512
[TBL] [Abstract][Full Text] [Related]
9. Anti-Angiogenic Therapy: Strategies to Develop Potent VEGFR-2 Tyrosine Kinase Inhibitors and Future Prospect.
Shi L; Zhou J; Wu J; Shen Y; Li X
Curr Med Chem; 2016; 23(10):1000-40. PubMed ID: 26860998
[TBL] [Abstract][Full Text] [Related]
10. A novel 2-aminobenzimidazole-based compound Jzu 17 exhibits anti-angiogenesis effects by targeting VEGFR-2 signalling.
Lien JC; Chung CL; Huang TF; Chang TC; Chen KC; Gao GY; Hsu MJ; Huang SW
Br J Pharmacol; 2019 Oct; 176(20):4034-4049. PubMed ID: 31368127
[TBL] [Abstract][Full Text] [Related]
11. Design, synthesis and biological evaluation of novel 4-anilinoquinazoline derivatives as hypoxia-selective EGFR and VEGFR-2 dual inhibitors.
Wei H; Duan Y; Gou W; Cui J; Ning H; Li D; Qin Y; Liu Q; Li Y
Eur J Med Chem; 2019 Nov; 181():111552. PubMed ID: 31387063
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of tumor cell growth and angiogenesis by 7-aminoalkoxy-4-aryloxy-quinazoline ureas, a novel series of multi-tyrosine kinase inhibitors.
Ravez S; Barczyk A; Six P; Cagnon A; Garofalo A; Goossens L; Depreux P
Eur J Med Chem; 2014 May; 79():369-81. PubMed ID: 24747748
[TBL] [Abstract][Full Text] [Related]
13. Design and biological evaluation of 3-substituted quinazoline-2,4(1
Hassan A; Mubarak FAF; Shehadi IA; Mosallam AM; Temairk H; Badr M; Abdelmonsef AH
J Enzyme Inhib Med Chem; 2023 Dec; 38(1):2189578. PubMed ID: 36919632
[TBL] [Abstract][Full Text] [Related]
14. Novel 5-anilinoquinazoline-8-nitro derivatives as inhibitors of VEGFR-2 tyrosine kinase: synthesis, biological evaluation and molecular docking.
Xi L; Zhang JQ; Liu ZC; Zhang JH; Yan JF; Jin Y; Lin J
Org Biomol Chem; 2013 Jul; 11(26):4367-78. PubMed ID: 23715382
[TBL] [Abstract][Full Text] [Related]
15. Fragment-based investigation of thiourea derivatives as VEGFR-2 inhibitors: a cross-validated approach of ligand-based and structure-based molecular modeling studies.
Banerjee S; Kejriwal S; Ghosh B; Lanka G; Jha T; Adhikari N
J Biomol Struct Dyn; 2024; 42(2):1047-1063. PubMed ID: 37029768
[TBL] [Abstract][Full Text] [Related]
16. In silico insights into the identification of potential novel angiogenic inhibitors against human VEGFR-2: a new SAR-based hierarchical clustering approach.
Konidala KK; Bommu UD; Pabbaraju N
J Recept Signal Transduct Res; 2018 Aug; 38(4):372-383. PubMed ID: 30396316
[TBL] [Abstract][Full Text] [Related]
17. Synthesis, Characterization of 4-Anilino-6,7-Dimethoxy Quinazoline Derivatives as Potential Anti-Angiogenic Agents.
Devegowda PS; Balaji KS; Prasanna DS; Swaroop TR; Kameshwar VH; Jayarama S; Siddalingaiah L; Rangappa KS
Anticancer Agents Med Chem; 2018 Feb; 17(14):1931-1941. PubMed ID: 28403784
[TBL] [Abstract][Full Text] [Related]
18. Design, Synthesis, In Vitro Anti-cancer Activity, ADMET Profile and Molecular Docking of Novel Triazolo[3,4-a]phthalazine Derivatives Targeting VEGFR-2 Enzyme.
El-Helby AA; Sakr H; Ayyad RRA; El-Adl K; Ali MM; Khedr F
Anticancer Agents Med Chem; 2018; 18(8):1184-1196. PubMed ID: 29651967
[TBL] [Abstract][Full Text] [Related]
19. VEGFR-2 inhibitors and the therapeutic applications thereof: a patent review (2012-2016).
Peng FW; Liu DK; Zhang QW; Xu YG; Shi L
Expert Opin Ther Pat; 2017 Sep; 27(9):987-1004. PubMed ID: 28621580
[TBL] [Abstract][Full Text] [Related]
20. Discovery of arylamide-5-anilinoquinazoline-8-nitro derivatives as VEGFR-2 kinase inhibitors: Synthesis, in vitro biological evaluation and molecular docking.
Zhao Y; Liu F; He G; Li K; Zhu C; Yu W; Zhang C; Xie M; Lin J; Zhang J; Jin Y
Bioorg Med Chem Lett; 2019 Dec; 29(23):126711. PubMed ID: 31668972
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
